Searchable abstracts of presentations at key conferences in endocrinology

ea0035p885 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Feelders Richard , Pivonello Rosario , Pedroncelli Alberto , Patino Heather , Ye Moncy , Aout Mounir , Fleseriu Maria

Background: Dopamine and somatostatin receptors on corticotroph pituitary adenomas are targets for medical treatment of Cushing’s disease (CD). Data indicate synergistic effects between pasireotide and cabergoline in improving biochemical control rates and clinical features in patients with CD.Objective: To evaluate safety and efficacy of pasireotide alone or with cabergoline in patients with CD.Methods: Patients: adults with ...

ea0037ep811 | Pituitary: clinical | ECE2015

Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease

Salgado Luiz R , Stalla Gunter K , Mazzuco Tania Longo , Geer Eliza B , Pedroncelli Alberto M , Ye Moncy , Kandra Albert , Limumpornpetch Padiporn

Background: Pasireotide (Signifor®), a multireceptor-targeted somatostatin analogue, was initially approved in Europe and the USA in 2012 for treating adult patients with Cushing’s disease for whom surgery is not an option/has failed. This ‘expanded-access’ study allowed patients to receive pasireotide until regulatory approval was obtained in their country, and collected further safety/efficacy data. Here we report an interim analysis of this on...